Skip to main content
MedPathMedPath Home
Clinical Trials/NCT02070679
NCT02070679
Completed
Phase 3

Efficacy of Vitamin E in Preventing Contrast-Induced Acute Kidney Injury Following Coronary Angiography

Urmia University of Medical Sciences2 sites in 1 country284 target enrollmentFebruary 2014
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsStable AnginaUnstable AnginaNon ST Segment Elevation Myocardial InfarctionPost MI
InterventionsVitamin E

Overview

Phase
Phase 3
Intervention
Vitamin E
Conditions
Stable Angina
Sponsor
Urmia University of Medical Sciences
Enrollment
284
Locations
2
Primary Endpoint
The development of CI-AKI in group receiving vitamin E compared with placebo
Status
Completed
Last Updated
10 years ago
OverviewInvestigatorsEligibility CriteriaArms & InterventionsOutcomesSitesSimilar Trials

Overview

Brief Summary

The purpose of this study is to evaluate the effect of vitamin E on preventing from incidence of contrast induced acute kidney injury (CI-AKI) in the patients who undergone coronary angiography.

Registry
clinicaltrials.gov
Start Date
February 2014
End Date
June 2015
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Chancellor of research

Mir Hossein Seyyed-Mohammadzad

Urmia University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • •All patients whon have either stable coronary artery disease (CAD) or recent acute coronary disease (ACS) and are scheduled for coronary angiography.
  • •Patients who have eGFR ≤60 ml/min/1.73 m2

Exclusion Criteria

  • •Allergy to contrast media
  • •Cardiogenic shock
  • •Pulmonary edema
  • •Overt cardiac failure or left ventricular ejection fraction ≤ 30%
  • •Acute kidney injury
  • •The history of receiving contrast media for any medical diagnostic or therapeutic procedures during previous 5 days
  • •The history of dialysis
  • •Being pregnant
  • •Having recent acute myocardial infarction
  • •Taking antioxidants and nephrotoxic drugs including NSAID and ACE-I on previous 2 days

Arms & Interventions

Vit-E

600 IU on 12 hours before angiography and 400 IU on 2 hours before angiography

Intervention: Vitamin E

Outcomes

Primary Outcomes

The development of CI-AKI in group receiving vitamin E compared with placebo

Time Frame: Within 72 hours after coronary angiography

Secondary Outcomes

  • Changes in the serum level of Cr and the amount of eGFR(Within 72 hours)

Study Sites (2)

Loading locations...

Similar Trials

Completed
Phase 3
Effect of vitamin E in preventing kidney problems in thalassemia patientsR94.4Condition 1: Thalassemia. Condition 2: Acute Kidney Injury. Condition 3: Fanconi syndrome. Condition 4: Abnormal Kidney function.Beta thalassemiaAcute kidney failure with tubular necrosisDisorders of amino-acid transportAbnormal results of kidney function studiesD56.1N17.0E72.0
IRCT20221111056466N1Arak University of Medical Sciences50
Completed
Not Applicable
Vitamin E Prevention of Visible Light PigmentationPigmentation From Visible Light
NCT01927679Innovaderm Research Inc.10
Completed
Not Applicable
effect of vitamin E in intraventricular hemorrhage in preterm neonatesIntraventricular hemorrahge.Intracranial (nontraumatic) haemorrhage of fetus and newborn, unspecified
IRCT2015042521910N2Vice Chancellor for research of Isfahan University of Medical Sciense30
Not yet recruiting
Phase 3
effect of vitamin E on the prevention of acute renal injury in patients with leukemia
IRCT20190717044255N7Arak University of Medical Sciences36
Completed
Phase 3
Investigating the effect of vitamin E in the prevention of kidney dysfunction in infants
IRCT20221220056875N1Arak University of Medical Sciences150